Valor pronóstico de la forma soluble del receptor activador de plasminógeno de uroquinasa (suPAR) en la predicción de eventos adversos a los 30 días en los servicios de urgencias hospitalarios

Álvarez-Kailis, Silvia; Paniagua-Arribas, Esther; Paderne-Díaz, Beatriz; Gómez-García, Gema; Varillas-Delgado, David; Padilla-Berdugo, Rosario.
Emergencias (Sant Vicenç dels Horts) ; 33(6): 477-479, dic. 2021. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-216320

Documentos relacionados

  1. What is circulating factor disease and how is it currently explained?
  2. Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease.
  3. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department.
  4. Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department.
  5. Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.
  6. Soluble urokinase plasminogen activator receptor (suPAR) in bronchoalveolar fluid and blood in critically ill patients-a prospective cohort study.
  7. Activatable Fluorescent Probes Targeting Urokinase-Type Plasminogen Activator Receptor on the Cell Membrane.
  8. Recent Advances in Targeting the Urokinase Plasminogen Activator with Nanotherapeutics.
  9. Stratifying patients for polypharmacy interventions: The case for a new biomarker?
  10. Soluble Urokinase-Type Plasminogen Activator Receptor as a Prognostic Marker of Ugandan Children at Risk of Severe and Fatal Malaria.